Chan D-C, Chang C H-C, Lim L-C, Brnabic A J M, Tsauo J-Y, Burge R, Hsiao F-Y, Jin L, Gürbüz S, Yang R-S
Superintendent Office, Chu-Tung Branch, National Taiwan University Hospital, Hsinchu County, Taiwan.
Department of Geriatrics and Gerontology, National Taiwan University Hospital, Taipei, Taiwan.
Osteoporos Int. 2016 Sep;27(9):2855-2865. doi: 10.1007/s00198-016-3611-x. Epub 2016 May 12.
Medication persistence and adherence are critical for osteoporosis outcomes. Using the Taiwan National Health Insurance Research Database, we found that persistence and adherence to teriparatide were low in Taiwanese patients with osteoporosis and that greater persistence and adherence were associated with a lower incidence of hip and other nonvertebral fractures.
The purpose of this study was to determine the persistence and adherence to teriparatide treatment in Taiwanese patients with osteoporosis, and to examine the association between persistence and adherence to teriparatide with fracture risks.
Medical and pharmacy claims for 4,692 patients with vertebral or hip fractures and teriparatide prescriptions between 2005 and 2008 were identified (Taiwan National Health Insurance Research Database). Persistence was the time from the start of treatment to the first 90-day gap between two teriparatide prescriptions. Adherence was the number of teriparatide pens (each pen is used over 1 month) prescribed over 24 months. Association of persistence and adherence to teriparatide with fracture incidence was assessed using adjusted Cox proportional hazards models.
The proportion of patients persisting with teriparatide for >6 months and >12 months was 44.6 and 24.9 %, respectively. Over 24 months, 53.6 % of patients were adherent for >6 months and 33.9 % were adherent for >12 months. Patients persisting for >12 months had a significantly lower incidence of hip (adjusted hazard ratio [HR], 0.61 [95 % confidence interval (CI), 0.40-0.93], P = 0.0229) and nonvertebral fracture (HR, 0.79 [95 % CI, 0.63-0.99], P = 0.0462) compared with those who persisted for ≤12 months. Patients adherent for >12 months had a lower incidence of hip (HR, 0.66 [95 % CI, 0.46-0.96], P = 0.0286) and nonvertebral fracture (HR, 0.81 [95 % CI, 0.66-0.99], P = 0.0377) compared with those adherent for ≤12 months.
Persistence and adherence to teriparatide over 24 months were low in Taiwanese patients with osteoporosis; greater adherence and persistence were associated with a lower incidence of nonvertebral fractures.
药物持续使用和依从性对骨质疏松症的治疗效果至关重要。利用台湾国民健康保险研究数据库,我们发现台湾骨质疏松症患者对特立帕肽的持续使用和依从性较低,且更高的持续使用和依从性与更低的髋部及其他非椎体骨折发生率相关。
本研究的目的是确定台湾骨质疏松症患者对特立帕肽治疗的持续使用情况和依从性,并研究特立帕肽的持续使用及依从性与骨折风险之间的关联。
通过台湾国民健康保险研究数据库,识别出2005年至2008年间4692例患有椎体或髋部骨折且开具了特立帕肽处方的患者的医疗和药房理赔记录。持续使用时间是指从开始治疗到两张特立帕肽处方之间首次出现90天间隔的时间。依从性是指24个月内开具的特立帕肽笔数(每支笔使用超过1个月)。使用校正后的Cox比例风险模型评估特立帕肽的持续使用和依从性与骨折发生率之间的关联。
特立帕肽持续使用超过6个月和超过12个月的患者比例分别为44.6%和24.9%。在24个月期间,53.6%的患者依从性超过6个月,33.9%的患者依从性超过12个月。与持续使用时间≤12个月的患者相比,持续使用时间>12个月的患者髋部骨折发生率显著较低(校正风险比[HR],0.61[95%置信区间(CI),0.40 - 0.93],P = 0.0229),非椎体骨折发生率也较低(HR,0.79[95%CI,0.63 - 0.99],P = 0.0462)。与依从性≤12个月的患者相比,依从性>12个月的患者髋部骨折发生率较低(HR,0.66[95%CI,0.46 - 0.96],P = 0.0286),非椎体骨折发生率也较低(HR,0.81[95%CI,0.66 - 0.99],P = 0.0377)。
台湾骨质疏松症患者在24个月内对特立帕肽的持续使用和依从性较低;更高的依从性和持续使用与更低的非椎体骨折发生率相关。